title: [Study on relationship between leukotrienes and exercise-induced asthma].
abstract: OBJECTIVE
  To explore the relationship between leukotriene (LT) and exercise-induced asthma.
  
  
  METHODS
  Twenty-two non-smoking asthmatic patients with a reproducible fall in FEV(1) after exercise by least 10% and 10 normal patients were enrolled. Urinary levels of leukotriene E4 were measured before and 2 hours after exercise. Twelve subjects received cysteinyl LT receptor antagonist Zafirlukast (Ancolate) 20 mg twice a day for three days. Standardized exercise challenge were performed after 72 hours. End points included (1) area under the percent fall in FEV(1) versus time curve (AUC 0-60 min), (2) time to recovery to within 5% of the pre-exercise baseline FEV(1) value, (3) and maximum percent fall in FEV(1) from pre-exercise baseline.
  
  
  RESULTS
  To exercise-induced aothma (EIA) group, urinary LTE4 in 2 hours after exercise were higher than that of in before exercise, P < 0.01. Urinary leukotriene E4 concentration before and 2 hours after exercise were higher than normal subjects. Zafirlukast can caused a significant reduction in AUC(0 - 60 min) (Aera under the FEV(1)-time curve for 0 to 60 minutes after exercise); caused a significant reduction in the maximum percent fall in FEV(1); and Zafirlukast resulted in a shorter time to recovery of FEV(1) to preexercise baseline.
  
  
  CONCLUSIONS
  There was an increase in urinary LTE4 during the 2 hours after exercise challenge; Zafirlukast can attenuate EIA. The results indicate that there is an important role of leukotriene in the pathogenesis of exercise-induced asthma.
authors.affiliation: Beijing Hospital, Beijing 100730, China.
authors.forename: Tieying
authors.initials: T
authors.lastname: Sun
authors.forename: Yanfei
authors.initials: Y
authors.lastname: Guo
authors.forename: Hongsheng
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001250:Asthma, Exercise-Induced / Q000517:prevention & control / Q000652:urine*; D005260:Female; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists; D017999:Leukotriene E4 / Q000652:urine*; D015289:Leukotrienes / Q000652:urine*; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D048448:Phenylcarbamates; D018077:Receptors, Leukotriene; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use
chemical_list: D018927:Anti-Asthmatic Agents; D007211:Indoles; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D008565:Membrane Proteins; D048448:Phenylcarbamates; D018077:Receptors, Leukotriene; D013449:Sulfonamides; D014105:Tosyl Compounds; D017999:Leukotriene E4; C412375:cysteinyl leukotriene receptor 2; C083169:leukotriene D4 receptor; C062735:zafirlukast